Selank

Description

Selank – research-grade investigational peptide

Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived from tuftsin, a naturally occurring tetrapeptide sequence, with the addition of a Pro-Gly-Pro fragment. Because of this structure, Selank is discussed in scientific research involving regulatory-peptide activity, neurotransmitter signalling and neuroimmune pathway analysis.

Within laboratory and preclinical research contexts, Selank is of interest due to studies examining GABA-related neurotransmission, brain-derived neurotrophic factor, commonly known as BDNF, and changes in neuronal gene expression. This makes it relevant for experimental research involving stress responses, cognitive processes, neurochemical regulation and communication between the nervous and immune systems.

Research relevance of Selank

Selank is commonly associated with:

• Investigation of GABA-related neurotransmission
• Studies involving BDNF and neurotrophic signalling
• Experimental analysis of stress- and anxiety-related behavioural models
• Research into learning, memory and cognitive-response pathways
• Investigation of neuroimmune and inflammation-related gene expression

Scientific research background

Scientific studies examining Selank have investigated its effects on genes associated with GABA receptors, neurotransmitter transporters, ion channels, dopamine and serotonin signalling. A rat study reported changes in numerous neurotransmission-related genes following Selank administration and proposed that one possible mechanism may involve modulation of the GABAergic system.

Separate animal research has examined Selank’s influence on BDNF expression in the hippocampus, learning and memory processes, monoamine metabolism and behavioural responses in experimental stress and dependency models. Research has also explored changes in inflammation-related gene expression in spleen tissue and immune-cell preparations.

The available evidence remains largely laboratory-based, preclinical or derived from limited and predominantly older human studies. Results depend on the precise peptide form, experimental model, concentration, research conditions, methodology and measured endpoints. These findings should not be interpreted as confirmed therapeutic outcomes in humans.

The FDA has stated that compounded preparations containing Selank acetate may present immunogenicity risks because of potential peptide aggregation and peptide-related impurities. The agency also reports that it lacks sufficient information concerning the safety of Selank acetate administered to humans. The exact sequence, salt form, identity and purity of research material should therefore be confirmed through appropriate analytical documentation.

Scientific reference

Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016;7:31.

FOR RESEARCH USE ONLY

IMPORTANT INFORMATION

• This substance is supplied strictly for laboratory research purposes.
• It is not a food product.
• It is not a dietary supplement.
• It is not an authorised medicinal product.
• It is not intended for human or animal consumption.
• It is not intended for injection, nasal administration or oral administration.
• The product name does not by itself confirm its identity, sequence, molecular form, concentration, purity or sterility.
• Keep out of reach of children.
• Keep the container sealed when not in use.
• Store in the original container only.
• Store according to the conditions stated on the product label or certificate of analysis.
• Protect from moisture, excessive heat and direct sunlight.
• Avoid handling during pregnancy or breastfeeding.

In the event of accidental exposure, irritation, illness or any adverse reaction, seek medical advice.